Stock listing

OTC:EGRX Eagle Pharmaceuticals, Inc. Stock

Follow Eagle Pharmaceuticals, Inc. into a list and get an email when it puts out news.

Share price · OTC:EGRX

$0.65 USD 0.00 (0.0%)

Close on Nov 20, 2026

Past year -16.7% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$0.40 – $0.65 USDNov 20, 2026
Volume
275 sharesNov 20, 2026
Market cap
$8.55M USDAt the close on Nov 20, 2026 · price × 13.16M shares outstanding
52-week range
$0.0010 – $3.94 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$1,491 USDMedian day 0 shares · 38 days with no trades · last 3 months, Aug 20, 2026 – Nov 20, 2026
Eagle Pharmaceuticals, Inc. logo

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · OTC:EGRX · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$0.650.000.0%$0.40$0.65$0.40275
$0.650.000.0%$0.65$0.65$0.650
$0.65-0.25-27.8%$0.45$0.65$0.452,400
$0.90+0.08+9.8%$0.21$0.90$0.21500
$0.820.000.0%$0.82$0.82$0.820
$0.820.000.0%$0.82$0.82$0.820
$0.820.000.0%$0.82$0.82$0.820
$0.82-0.08-8.9%$0.25$0.86$0.25900
$0.90-0.05-5.3%$0.21$0.90$0.21300
$0.950.000.0%$0.95$0.95$0.950
$0.950.000.0%$0.95$0.95$0.950
$0.950.000.0%$0.95$0.95$0.950
$0.950.000.0%$0.95$0.95$0.950
$0.950.000.0%$0.95$0.95$0.950
$0.950.000.0%$0.95$0.95$0.950
$0.950.000.0%$0.95$0.95$0.950
$0.950.000.0%$0.95$0.95$0.950
$0.95-0.05-5.0%$0.0020$0.975$0.00203,900
$1.000.000.0%$1.00$1.00$1.000
$1.00-2.935-74.6%$0.95$1.00$0.95200
$3.935+3.05+344.6%$0.70$3.935$0.701,600
$0.8850.000.0%$0.885$0.885$0.8850
$0.8850.000.0%$0.885$0.885$0.8850
$0.885+0.005+0.6%$0.60$0.885$0.604,900
$0.880.000.0%$0.88$0.88$0.880
$0.88-0.005-0.6%$0.11$0.88$0.114,300
$0.885-0.085-8.8%$0.181$0.885$0.1813,300
$0.970.000.0%$0.97$0.97$0.970
$0.970.000.0%$0.97$0.97$0.970
$0.970.000.0%$0.97$0.97$0.970
$0.970.000.0%$0.97$0.97$0.970
$0.970.000.0%$0.97$0.97$0.970
$0.970.000.0%$0.97$0.97$0.970
$0.97+0.01+1.0%$0.21$0.97$0.211,400
$0.96+0.01+1.1%$0.75$0.96$0.6653,500
$0.95-0.075-7.3%$0.18$0.975$0.187,300
$1.0250.000.0%$1.025$1.025$1.0250
$1.0250.000.0%$1.025$1.025$1.0250
$1.025+0.125+13.9%$0.975$1.025$0.97516,000
$0.900.000.0%$0.90$0.90$0.904,100
$0.900.000.0%$0.18$0.90$0.18300
$0.900.000.0%$0.90$0.90$0.900
$0.90-0.385-30.0%$0.40$0.90$0.403,500
$1.2850.000.0%$1.285$1.285$1.2850
$1.2850.000.0%$1.285$1.285$1.2850
$1.2850.000.0%$1.285$1.285$1.2850
$1.2850.000.0%$1.285$1.285$1.2850
$1.285+0.53+70.2%$0.18$1.285$0.18800
$0.755+0.005+0.7%$0.18$0.755$0.185,900
$0.750.000.0%$0.75$0.75$0.750
$0.750.000.0%$0.75$0.75$0.750
$0.750.000.0%$0.75$0.75$0.750
$0.75-0.165-18.0%$0.17$0.90$0.171,100
$0.915-0.01-1.1%$0.40$0.915$0.4016,100
$0.9250.000.0%$0.925$0.925$0.9250
$0.9250.000.0%$0.925$0.925$0.9250
$0.9250.000.0%$0.925$0.925$0.9250
$0.925+0.24+35.0%$0.18$0.925$0.1810,300
$0.685+0.155+29.2%$0.37$0.685$0.373,800
$0.530.000.0%$0.53$0.53$0.530
$0.530.000.0%$0.53$0.53$0.530
$0.530.000.0%$0.53$0.53$0.530
$0.53-0.065-10.9%$0.15$0.53$0.152,200
Ticker
OTC:EGRX
Asset type
Stock
Sector
Health care
Industry
Pharmaceuticals
Exchange
OTC
Currency
USD

What changed lately

Latest news

All Eagle Pharmaceuticals, Inc. news

Eagle Pharmaceuticals, Inc. on 6ix

Sector
Health care
Industry
Pharmaceuticals
News releases
1 in the last 12 months · 1 in all · newest Oct 30, 2026 · oldest 2026
Calls
12 calls with a replay · 12 with a transcript · latest Aug 8, 2023
Decks
47 decks · latest Sep 27, 2023

Valuation

price Nov 20, 2026

Enterprise value
No statements on 6ix yet
P/E
No statements on 6ix yet
EV/sales
No statements on 6ix yet
EV/EBITDA
No statements on 6ix yet
Price/book
No statements on 6ix yet
Gross margin
No statements on 6ix yet
Operating margin
No statements on 6ix yet
Net margin
No statements on 6ix yet
Debt to equity
No statements on 6ix yet
Beta vs S&P 500
0.20

Pharmaceuticals: the 10 companies nearest in size, of 492 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Eagle Pharmaceuticals, Inc. · OTC:EGRXUS$8.55Mn/an/an/an/an/an/an/a0.20
PT Phapros Tbk · IDX:PEHAUS$12.79MUS$41.58M4.5×0.7×4.6×0.5×5.0%1.5×n/a
PT Ikapharmindo Putramas Tbk · IDX:IKPMUS$11.81MUS$10.76Mn/an/an/a0.9×n/a0.0×n/a
Alpa Laboratories Limited · NSE:ALPAUS$11.33MUS$11.33M24.0×0.9×12.2×0.6×3.8%0.0×n/a
Advicenne SA · EURONEXT:ALDVIUS$10.53MUS$32.08Mn/a4.9×n/an/a−158.7%n/an/a
Biofrontera Inc. · NASDAQ:BFRIUS$9.51MUS$13.83Mn/a0.3×n/an/a−12.7%n/a1.96
Optimi Health Corp. · CSE:OPTIUS$9.18MUS$67,058n/a0.6×n/a0.8×n/a0.0×1.08
ChoA Pharmaceutical Co., Ltd. · KRX:034940US$6.59MUS$6.89Mn/a0.1×n/a0.3×−4.6%0.1×n/a
Newbury Pharmaceuticals AB · OMXSTO:NEWBRYUS$5.78MUS$4.87Mn/a1.2×n/a3.0×−53.7%0.0×n/a
Firebrick Pharma Limited · ASX:FREUS$5.51MUS$4.63Mn/a66.0×n/a5.0×n/a0.0×n/a
Universe Pharmaceuticals INC · NASDAQ:UPCUS$5.41M−US$14.09Mn/a0.0×n/a0.1×−20.6%0.2×0.91
Median of the othersUS$9.35MUS$8.83M14.2×0.7×8.4×0.7×−12.7%0.0×1.08

Team and board

Officers

OfficerRole
Michael GravesChairman of the Board, Chief Executive Officer
Christopher KrawtschukChief Financial Officer
Daniel O’ConnorChief Strategy Officer, Head of Corporate Development

Board

DirectorRole
Michael GravesChairman of the Board, Chief Executive Officer
Jennifer SimpsonBoard Member, Lead Independent Director of the Board
Luciana BorioBoard Member, Strategic Clinical Development Committee Chair
Richard A. EdlinBoard Member
Robert L. GlenningBoard Member, Audit Committee Chair
Steven RatoffBoard Member

Events

Results days

QuarterResultsShare move
Quarter to Mar 31, 2026May 11, 2026−1.3%
Quarter to Dec 31, 2025Mar 9, 2026+127.3%
Quarter to Sep 30, 2025Oct 16, 20250.0%
Quarter to Jun 30, 2025Aug 29, 2025+0.2%
Quarter to Mar 31, 2025May 30, 2025+5.3%
Quarter to Dec 31, 2024Mar 10, 2025+21.2%
Quarter to Sep 30, 2024Nov 29, 2024+5.6%
Quarter to Jun 30, 2024Aug 6, 2024−2.5%
Quarter to Mar 31, 2024May 7, 2024+3.9%
Quarter to Dec 31, 2023Feb 28, 2024−9.0%
All 20 quarters
QuarterResultsShare move
Quarter to Sep 30, 2023Dec 8, 2023 · Before open−2.7%
Q2 2023Aug 8, 2023 · Before open+4.9%
Q1 2023May 9, 2023 · Before open−13.3%
Q4 2022Mar 13, 2023 · Before open+1.8%
Q3 2022Nov 7, 2022 · Before open+25.9%
Q2 2022Aug 9, 2022 · Before open−14.5%
Q1 2022May 9, 2022 · Before open−0.7%
Q4 2021Mar 7, 2022 · Before open+5.9%
Q3 2021Nov 9, 2021 · Before open+0.6%
Q2 2021Aug 9, 2021 · Before open+4.5%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (September 2023)Investor deck21 slidesSep 27, 2023
Investor Presentation (September 2023)Investor deck20 slidesSep 7, 2023
Investor Presentation (June 2023)Investor deck16 slidesJun 7, 2023
J.P. Morgan Healthcare Conference January 2023Conference14 slidesJan 10, 2023
J.P. Morgan Healthcare Conference January 2023Conference14 slidesJan 9, 2023
Investor Day (December 2022)Investor day144 slidesDec 6, 2022
Investor Presentation (June 2022)Investor deck10 slidesJun 9, 2022
Merger or Acquisition (March 2022)Merger or acquisition32 slidesMar 31, 2022
Investor Presentation (January 2022)Investor deck29 slidesJan 11, 2022
Investor Presentation (October 2021)Investor deck32 slidesOct 14, 2021
All 47 decks
DeckKindSlidesDate
Technical Presentation (September 2021)Technical43 slidesSep 9, 2021
Corporate Update (March 2021)Corporate update9 slidesMar 2, 2021
Q4 2020 Earnings PresentationEarnings31 slidesMar 2, 2021
Investor Presentation (September 2020)Investor deck31 slidesSep 14, 2020
Investor Presentation (June 2020)Investor deck33 slidesJun 1, 2020
Investor Presentation (May 2020)Investor deck33 slidesMay 19, 2020
J.P. Morgan Healthcare Conference 2020Conference34 slidesJan 13, 2020
Investor Presentation (October 2019)Investor deck28 slidesOct 21, 2019
Investor Presentation (June 2019)Investor deck23 slidesJun 4, 2019
Investor Presentation (May 2019)Investor deck26 slidesMay 8, 2019
Investor Presentation (February 2019)Investor deck25 slidesFeb 21, 2019
Investor Presentation (November 2018)Investor deck24 slidesNov 8, 2018
Investor Presentation (September 2018)Investor deck20 slidesSep 13, 2018
Investor Presentation (March 2018)Investor deck21 slidesMar 7, 2018
Investor Presentation (January 2018)Investor deck22 slidesJan 8, 2018
Investor Presentation (September 2017)Investor deck21 slidesSep 13, 2017
Corporate Update (January 2017)Corporate update22 slidesJan 11, 2017
Investor Day (November 2016)Investor day116 slidesNov 14, 2016
Investor Presentation (September 2016)Investor deck23 slidesSep 13, 2016
Investor Presentation (August 2016)Investor deck23 slidesAug 10, 2016
Investor Presentation (June 2016)Investor deck25 slidesJun 8, 2016
Investor Presentation (May 2016)Investor deck24 slidesMay 3, 2016
Investor Presentation (May 2016)Investor deck24 slidesMay 2016
Investor Presentation (April 2016)Investor deck24 slidesApr 21, 2016
Investor Presentation (March 2016)Investor deck20 slidesMar 24, 2016
Investor Presentation (February 2016)Investor deck19 slidesFeb 23, 2016
Investor Presentation (February 2016)Investor deck19 slidesFebruary 2016
JPMorgan Healthcare Conference 2016Conference19 slidesJanuary 2016
Investor Presentation (September 2015)Investor deck16 slidesSep 21, 2015
Investor Presentation (June 2015)Investor deck18 slidesJune 2015
Investor Presentation (March 2015)Investor deck21 slidesMar 30, 2015
Investor Presentation (January 2015)Investor deck20 slidesJan 12, 2015
Investor Presentation (November 2014)Investor deck20 slidesNov 19, 2014
Investor Presentation (September 2014)Investor deck18 slidesSep 26, 2014
Investor Presentation (September 2014)Investor deck18 slidesSeptember 2014
Jefferies 2014 Global Healthcare ConferenceConference19 slidesJun 5, 2014
Investor Presentation (May 2014)Investor deck14 slidesMay 8, 2014

Open Decks

Financials

Annual, in USD

Income statement

LineFY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015FY2014FY2013
Revenue316.6M171.5M187.8M195.9M213.3M236.7M189.5M66.2M19.1M13.7M
Cost of revenue94.9M42.2M45.5M60.9M61.9M57.2M55.3M15.6M11.7M7.38M
Gross profit221.7M129.4M142.3M135.0M151.4M179.5M134.2M50.6M7.38M6.30M
Research and development34.1M51.3M30.8M36.8M44.4M32.6M30.3M27.9M16.8M9.80M
Selling, general and administrative98.1M66.8M75.9M74.0M57.2M73.1M37.5M15.4M5.02M14.8M
Operating income81.0M2.77M33.0M21.8M36.6M74.0M53.4M2.56M-18.8M-8.46M
Depreciation and amortization12.0M3.76M4.77M4.65M3.67M3.75M1.59M112.0K104.0K135.0K
EBITDA93.0M6.53M37.7M26.5M40.3M77.7M54.9M2.67M-18.7M-8.32M
Interest expense4.04M1.64M2.58M2.69M2.74M1.14M8.00K11.0K8.00K1.40M
Income before tax61.4M-4.55M22.7M22.0M34.0M72.9M53.4M2.57M-19.3M-6.95M
Income tax25.8M4.08M10.7M7.68M2.13M21.0M-28.0M3.00K-1.29M-898.7K
Net income35.6M-8.63M12.0M14.3M31.9M51.9M81.5M2.57M-18.0M-6.05M
Earnings per share, basic2.73-0.660.871.012.093.274.960.16-1.81-0.57

Balance sheet

LineFY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015FY2014FY2013
Cash and equivalents55.3M97.7M103.2M109.8M78.8M114.7M52.8M79.1M22.7M10.5M
Short-term investments4.98M00020.0M
Receivables73.4M41.5M51.1M48.0M66.5M53.8M42.2M26.3M7.30M5.12M
Inventory47.8M21.9M8.07M6.57M8.30M5.12M2.74M15.0M1.29M1.87M
Current assets188.8M172.6M166.1M179.4M163.8M188.7M109.1M122.3M53.0M17.5M
Property, plant and equipment1.17M1.64M2.08M2.20M2.40M6.82M3.32M2.21M344.0K402.0K
Goodwill45.0M39.7M39.7M39.7M39.7M39.7M39.7M039.7M
Total assets406.2M253.7M253.2M254.6M238.6M270.1M213.6M124.6M53.4M18.1M
Accounts payable19.0M16.4M6.27M5.46M9.92M12.0M14.7M3.94M4.06M1.19M
Current liabilities111.1M74.4M38.1M38.8M39.7M47.3M40.2M34.3M20.3M14.3M
Long-term debt56.2M25.1M33.6M38.2M42.9M0001.71M
Total debt67.8M29.8M38.2M38.6M44.4M47.8M
Total liabilities172.6M77.3M67.2M75.4M77.8M90.9M62.3M34.3M20.3M16.0M
Shareholders' equity233.6M176.5M186.0M179.2M160.8M179.1M151.2M90.3M33.1M2.05M
Shares outstanding13.1M13.1M13.8M14.1M15.3M15.9M16.4M16.3M9.96M10.6M

Cash flow

LineFY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015FY2014FY2013
Cash from operations50.7M28.2M49.5M56.0M52.4M58.9M53.2M-9.72M-13.8M-5.88M
Capital spending-178.0K-323.0K-747.0K-777.0K-133.0K-5.19M-20.7M-1.88M-46.0K-40.5K
Free cash flow50.5M27.9M48.8M55.2M52.3M53.7M32.5M-11.6M-13.9M-5.92M
Cash from investing-86.8M-5.32M-18.2M-777.0K-133.0K-5.19M-45.8M-1.88M-20.0M1.46M
Cash from financing-6.21M-28.4M-37.9M-24.2M-88.1M8.10M-33.7M55.8M46.2M9.81M
Dividends paid-1.75M-2.40M-3.65M-260.0K0000
Share buybacks-18.0M-21.2M-35.0M-18.0M-73.1M-43.8M-37.0M55.8M46.2M
Change in cash-42.3M-5.50M-6.62M31.0M-35.9M61.8M-26.3M44.2M12.3M5.39M

Open Financials

Cap table

Built by 6ix from Eagle Pharmaceuticals, Inc.’s releases

Common shares
13,157,553
Fully diluted
13,157,553

Fully diluted

LineShares
Common shares13,157,553

Share count over time

CountShares
Nov 22, 202613,157,553

Open Cap table

Shareholders

HolderSharesOf the companyValueAs of
Stanley-Laman Group, Ltd.12,0000.09%US$11,400Sep 30, 2026
Archer Investment Corp350<0.01%US$333Sep 30, 2026

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Douglas L Braunstein
Other companies: Talkspace, Inc. (Director · Since at least Jun 22, 2021); Hudson Executive Investment Corp II (Director · Mar 11, 2021 – Feb 7, 2022 · Past); Hudson Executive Investment Corp III (Director · Feb 23, 2021 – Mar 2, 2022 · Past); Cardtronics plc (Director · Aug 8, 2018 – Jun 25, 2020 · Past); Corindus Vascular Robotics Inc (Director · Mar 16, 2018 – Oct 29, 2019 · Past); JPMorgan Chase & Co. (Chief Financial Officer · Jun 22, 2010 – Dec 17, 2012 · Past)
Director · Jul 5, 2016 – Oct 24, 2019 · Past
Jennifer Simpson
Other companies: LadRx Corporation (Director · Jan 15, 2024 – Jan 15, 2024 · Past); Panbela Therapeutics, Inc. (President and CEO, Director · Mar 30, 2021 – Oct 1, 2024 · Past); Delcath Systems, Inc. (President and CEO, Director · Mar 23, 2012 – May 6, 2020 · Past)
Board Member, Lead Independent Director of the Board · Since at least Aug 28, 2019
Sander A Flaum
Other companies: Viasys Healthcare Inc (Director · May 11, 2006 – Jun 28, 2007 · Past)
Director · Feb 11, 2014 – Mar 5, 2019 · Past
Brian Joseph CahillCHIEF FINANCIAL OFFICER · Oct 29, 2020 – Feb 27, 2024 · Past
Christopher KrawtschukChief Financial Officer · Since at least Nov 5, 2026
Daniel O’ConnorChief Strategy Officer, Head of Corporate Development · Since at least Nov 5, 2026
David E RiggsChief Financial Officer · Feb 11, 2014 – Jan 4, 2017 · Past
Luciana BorioBoard Member, Strategic Clinical Development Committee Chair · Since at least Nov 5, 2026
Michael GravesChairman of the Board, Chief Executive Officer · Since at least Feb 11, 2014
Richard A. EdlinBoard Member · Since at least Nov 5, 2026
All 14 people
PersonSeat
Robert L. GlenningBoard Member, Audit Committee Chair · Since at least Jul 5, 2016
Steven B RatoffDirector · Jan 4, 2016 – Mar 7, 2023 · Past
Steven L KrillEVP & Chief Scientific Officer · Feb 11, 2014 – Jan 7, 2018 · Past
Steven RatoffBoard Member · Since at least Nov 4, 2026

Open People

Log in to ask 6ix AI your own questions about Eagle Pharmaceuticals, Inc.